Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
CA 2422890 C · Owner: Baylin, Stephen B. · Inventors: Baylin, Stephen B.; Herman, James G.; Esteller, Manel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a method of predicting a clinical response for treatment of a , cancer with an alkylating chemotherapeutic agent. The method comprises determining the state , of methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene in the cancer, wherein methylation of the MGMT gene is predictive of an effective or a positive clinical , response to the alkylating chemotherapeutic agent in the treatment of the cancer. Figure 1 shows , the overall survival among subjects with gliomas treated with carmustine and , the time of , progression of disease according to the methylation status of the MGMT promoter.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 1, 2001 and granted April 23, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 1, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 1, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.